Tigermed Expands Global Reach with Strategic Acquisition of Micron in Japan
On July 29, 2025, Tigermed, a renowned provider of clinical research solutions, announced the successful acquisition of Micron, a notable Contract Research Organization (CRO) based in Japan. This strategic move is set to fortify Tigermed's position in the Asian biopharmaceutical landscape by enhancing its expertise in medical imaging and clinical trial services.
Founded in 2005 and headquartered in Tokyo, Micron has established itself as a frontrunner in the field, supporting over 250 clients and contributing to the approval of more than 40 drugs. The firm’s extensive experience spans nearly two decades, specializing in medical imaging, an essential aspect of clinical trials that significantly impacts drug development processes. Micron boasts Asia's largest team of imaging experts, renowned for its technological excellence and pioneering practices in various imaging biomarkers and AI-supported imaging.
With over 160 dedicated employees, Micron's strengths align perfectly with Tigermed's mission of providing comprehensive research and development solutions. According to Mr. Hiroaki Suzuki, President and Co-founder of Micron, the integration into Tigermed presents a remarkable opportunity for growth and collaboration. He stated, "Micron is committed to human health by supporting research activities in the medical field through utilizing imaging technologies. We believe our 20 years of medical imaging experience will become a strong support to Tigermed in this sector."
Following the acquisition, Micron will operate under the banner of Tigermed Japan, integrating into their extensive global network. This move is anticipated to expand Tigermed's service offerings throughout Japan and the broader Asia-Pacific region, amplifying their medical imaging capabilities. Mr. Michael Wen, Co-President of Tigermed, expressed excitement over the acquisition, highlighting that Micron's unique strengths would significantly aid their business expansion in Japan. He remarked, "The integration of our technologies and talent will comprehensively enhance our competitiveness in medical imaging and clinical services, empowering us to make greater contributions to global medical research and development."
Tigermed's operational landscape currently spans over 180 global locations, engaging with more than 3,600 customers, and employing over 10,000 staff across multiple continents. The company emphasizes a commitment to facilitating the developmental journey of biopharmaceutical and medical device innovations efficiently and cost-effectively. By incorporating Micron into its operations, Tigermed aims to leverage the deep regional insights and established processes of Micron, amplifying its presence within a critical market.
In addition to providing support for clinical trials, Micron is significant in niche sectors, including theranostic clinical trials that advance personalized medicine. This alignment with Tigermed’s strategic vision underlines a mutual commitment to revolutionizing healthcare through advanced technology and comprehensive research methodologies.
Overall, this acquisition marks a pivotal moment for Tigermed, enabling it to bolster its capabilities in medical imaging and expand its footprint in a vital region. The collaboration not only enhances operational efficiency but also presents new opportunities to pursue innovations in clinical research and development, benefiting stakeholders across the pharmaceutical and medical device industries. With a combined vision for the future, Tigermed and Micron are poised to make substantial strides in the realm of clinical research, ultimately contributing to improved health outcomes worldwide.
For more detailed information about Tigermed's services, visit their official website www.tigermedgrp.com, and for insights on Micron’s offerings, check out www.microncro.com.
Founded in 2005 and headquartered in Tokyo, Micron has established itself as a frontrunner in the field, supporting over 250 clients and contributing to the approval of more than 40 drugs. The firm’s extensive experience spans nearly two decades, specializing in medical imaging, an essential aspect of clinical trials that significantly impacts drug development processes. Micron boasts Asia's largest team of imaging experts, renowned for its technological excellence and pioneering practices in various imaging biomarkers and AI-supported imaging.
With over 160 dedicated employees, Micron's strengths align perfectly with Tigermed's mission of providing comprehensive research and development solutions. According to Mr. Hiroaki Suzuki, President and Co-founder of Micron, the integration into Tigermed presents a remarkable opportunity for growth and collaboration. He stated, "Micron is committed to human health by supporting research activities in the medical field through utilizing imaging technologies. We believe our 20 years of medical imaging experience will become a strong support to Tigermed in this sector."
Following the acquisition, Micron will operate under the banner of Tigermed Japan, integrating into their extensive global network. This move is anticipated to expand Tigermed's service offerings throughout Japan and the broader Asia-Pacific region, amplifying their medical imaging capabilities. Mr. Michael Wen, Co-President of Tigermed, expressed excitement over the acquisition, highlighting that Micron's unique strengths would significantly aid their business expansion in Japan. He remarked, "The integration of our technologies and talent will comprehensively enhance our competitiveness in medical imaging and clinical services, empowering us to make greater contributions to global medical research and development."
Tigermed's operational landscape currently spans over 180 global locations, engaging with more than 3,600 customers, and employing over 10,000 staff across multiple continents. The company emphasizes a commitment to facilitating the developmental journey of biopharmaceutical and medical device innovations efficiently and cost-effectively. By incorporating Micron into its operations, Tigermed aims to leverage the deep regional insights and established processes of Micron, amplifying its presence within a critical market.
In addition to providing support for clinical trials, Micron is significant in niche sectors, including theranostic clinical trials that advance personalized medicine. This alignment with Tigermed’s strategic vision underlines a mutual commitment to revolutionizing healthcare through advanced technology and comprehensive research methodologies.
Overall, this acquisition marks a pivotal moment for Tigermed, enabling it to bolster its capabilities in medical imaging and expand its footprint in a vital region. The collaboration not only enhances operational efficiency but also presents new opportunities to pursue innovations in clinical research and development, benefiting stakeholders across the pharmaceutical and medical device industries. With a combined vision for the future, Tigermed and Micron are poised to make substantial strides in the realm of clinical research, ultimately contributing to improved health outcomes worldwide.
For more detailed information about Tigermed's services, visit their official website www.tigermedgrp.com, and for insights on Micron’s offerings, check out www.microncro.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.